GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Price-to-Owner-Earnings

Thiogenesis Therapeutics (TSXV:TTI) Price-to-Owner-Earnings : (As of May. 10, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Price-to-Owner-Earnings?

As of today (2025-05-10), Thiogenesis Therapeutics's share price is C$0.65. Thiogenesis Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Thiogenesis Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


TSXV:TTI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 29.66
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-10), Thiogenesis Therapeutics's share price is C$0.65. Thiogenesis Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.07. Therefore, Thiogenesis Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-10), Thiogenesis Therapeutics's share price is C$0.65. Thiogenesis Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was C$-0.07. Therefore, Thiogenesis Therapeutics's PE Ratio without NRI for today is At Loss.


Thiogenesis Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Thiogenesis Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Price-to-Owner-Earnings Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23
Price-to-Owner-Earnings
- - - - -

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Thiogenesis Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Thiogenesis Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thiogenesis Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Price-to-Owner-Earnings falls into.


;
;

Thiogenesis Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Thiogenesis Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.65/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thiogenesis Therapeutics  (TSXV:TTI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Thiogenesis Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Thiogenesis Therapeutics Business Description

Traded in Other Exchanges
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder